Rinvoq (upadacitinib) 15 mg film-coated tablets, 28 tablets, generic, India Rheumatoid arthritis Delivery of medications from Europe and beyond within 4-5 days, guaranteed storage conditions, payment upon receipt. Order by calling +380996042415, Viber, WhatsApp.

Rheumatoid arthritis

RINVOK® indications for the treatment of rheumatoid arthritis of moderate to high level of activity in adult patients, if adequate response has not been withdrawn or there is an underlying intolerance to one or several anti-rheumatic drugs drugs that modify disease progression (DMARDs – disease-modifying antirheumatic drugs).

RINVOK® can be given as monotherapy or in combination with methotrexate.

Psoriatic arthritis

RINVOK® indications for the treatment of active psoriatic arthritis in adult patients in whom there is an inadequate response or intolerance to one or several anti-rheumatic drugs that modify the disease sickness RINVOK® can be used as monotherapy or in combination with methotrexate.

Axial spondyloarthritis

Non-radiographic axial spondyloarthritis (nr-axSA)

RINVOK® indications for the treatment of active non-radiographic axial spondyloarthritis in adults with objective signs of inflammation, confirmed by an elevated level of C-reactive protein (CRP) and/or MRI data, and with inadequate Submit for therapy non-steroidal anti-inflammatory drugs (NSAIDs).

Ankylosive spondylitis (AS, radiographic axial spondylitis)

RINVOK® indications for the treatment of active ankylosive spondylitis in adult patients with inadequate response to standard therapy.

Atopic dermatitis

RINVOK® indications for the treatment of moderate to severe atopic dermatitis in adults and children of all ages 12 patients who are candidates for systemic therapy.

Viraskovic colitis

RINVOK® indications for the treatment of viral colitis with mild or pronounced activity in adult patients with inadequate subtype, subtype or intolerance to standard therapy or biological drugs.

Khvoroba Crohn's disease

RINVOK® indications for treatment of moderate and severe Crohn's disease activity in adult patients due to inadequate response, loss of response, or intolerance to standard therapy

or biological preparations.